Crossmark

Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: clinical outcomes in a single centre cohort after long-term follow-up

Crossref DOI link: https://doi.org/10.1186/s12872-020-01448-7

Published Online: 2020-04-10

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Corrochano, M.

Jiménez, B.

Millón, J.

Gich, I.

Rambla, M.

Gil, E.

Caparrós, P.

Macho, R.

Souto, J. C.
License Information

Text and Data Mining valid from 2020-04-10

Version of Record valid from 2020-04-10
More Information

Article History

Received: 18 February 2019

Accepted: 26 March 2020

First Online: 10 April 2020

Ethics approval and consent to participate

: The study was carried out following rigorously the international ethical recommendations for medical research in humans. The researchers were responsible for ensuring that the study was conducted in accordance with the standards set out in the Declaration of Helsinki. Before starting the study, the Ethical Committee of the Hospital de la Santa Creu i Sant Pau approved the study protocol.

: Not applicable.

: The authors report the following general conflicts: JCS has received speaker honoraria or consultancy fees from Roche Diagnostics, Astra Zeneca, Sanofi-Aventis, Daiichi-Sankyo and Rovi. Also, financial support to attend scientific congresses from Boehringer Ingelheim, Leo Pharma, Pfizer, Bristol Myers Squibb and Baxter. He was Scientific Director of Monitor Medical and is now scientific and clinical advisor in Devicare. MC has received financial support to attend scientific congresses from Rovi and Novartis. JM has received financial support to attend scientific meetings and congresses from Pfizer, Boehringer Ingelheim, Bayer and Rovi.

Document is current

Any future updates will be listed below